Drugs / ZB002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05638854 | Dec 2022 → Jul 2025 overdue | rheumatoid arthritis | Zenas BioPharma (USA), LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZB002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05638854 ↗ |
| Route | Subcutaneous | “ZB002 will be administered subcutaneously” NCT05638854 ↗ |